Page last updated: 2024-11-05

trientine and Aprosodia

trientine has been researched along with Aprosodia in 2 studies

Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.

Research Excerpts

Excerpt	Relevance	Reference
"Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients who present with neurologic disease."	2.72	Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. ( Askari, F; Brewer, GJ; Carlson, M; Dick, RB; Fink, JK; Hedera, P; Kluin, KJ; Lorincz, MT; Moretti, P; Schilsky, M; Sitterly, J; Tankanow, R, 2006)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Sharawat, IK	1
Kurup, A	1
Sondhi, V	1
Saini, L	1
Brewer, GJ	1
Askari, F	1
Lorincz, MT	1
Carlson, M	1
Schilsky, M	1
Kluin, KJ	1
Hedera, P	1
Moretti, P	1
Fink, JK	1
Tankanow, R	1
Dick, RB	1
Sitterly, J	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT00004339]	Phase 3	90 participants	Interventional	1994-01-31	Completed
Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease[NCT01472874]		8 participants (Actual)	Interventional	2010-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Albumin

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Intervention	g/dL (Mean)
Once a Day Trientine	0.52

Albumin

(NCT01472874)
Timeframe: Pre Treatment (mean)

Intervention	g/dL (Mean)
Once a Day Trientine	0.54

ALT

Alanine transaminase (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Intervention	U/L (Mean)
Once a Day Trientine	50.89

ALT

Alanine transaminase (NCT01472874)
Timeframe: Pre Treatment (mean)

Intervention	U/L (Mean)
Once a Day Trientine	41.38

Cu Serum

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Intervention	mcg/24h (Mean)
Once a Day Trientine	0.52

Cu Serum

(NCT01472874)
Timeframe: Pre Treatment (mean)

Intervention	mcg/24h (Mean)
Once a Day Trientine	0.54

Cu Urine

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Intervention	mcg/24hr (Mean)
Once a Day Trientine	313.4

Cu Urine

(NCT01472874)
Timeframe: Pre Treatment (mean)

Intervention	mcg/24hr (Mean)
Once a Day Trientine	287.9

INR

The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Intervention	international normalized ratio (Mean)
Once a Day Trientine	1.05

INR

Intervention	international normalized ratio (Mean)
Once a Day Trientine	0.99

Zn Urine

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Intervention	mcg/24hr (Mean)
Once a Day Trientine	2214

Zn Urine

(NCT01472874)
Timeframe: Pre Treatment (mean)

Intervention	mcg/24hr (Mean)
Once a Day Trientine	1959

Trials

1 trial available for trientine and Aprosodia

Article	Year
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of neurology, 2006, Volume: 63, Issue:4 Topics: Adolescent; Adult; Anemia; Chelating Agents; Copper; Dose-Response Relationship, Drug; Double-Blind	2006
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of neurology, 2006, Volume: 63, Issue:4 Topics: Adolescent; Adult; Anemia; Chelating Agents; Copper; Dose-Response Relationship, Drug; Double-Blind	2006
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of neurology, 2006, Volume: 63, Issue:4 Topics: Adolescent; Adult; Anemia; Chelating Agents; Copper; Dose-Response Relationship, Drug; Double-Blind	2006
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of neurology, 2006, Volume: 63, Issue:4 Topics: Adolescent; Adult; Anemia; Chelating Agents; Copper; Dose-Response Relationship, Drug; Double-Blind	2006

Other Studies

1 other study available for trientine and Aprosodia

Article	Year
Boy with Dysarthria and Frequent Falls: A Treatable Disorder. The Journal of pediatrics, 2019, Volume: 215 Topics: Accidental Falls; Brain; Chelating Agents; Child; Dysarthria; Hepatolenticular Degeneration; Humans;	2019